TRIBBLES 2, A NOVEL TARGET FOR THERAPY OF ENZALUTAMIDE-RESISTANT NEUROENDOCRINE PROSTATE CANCER

$1,128,417FY2022Defense Health AgencyDOD

Henry Ford Health System, Detroit MI

Investigators